Prostate Cell News Volume 7.32 | Sep 2 2016

TOP STORY

Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo Resistance and Inhibits Tumor Development in TRAMP Mice

Researchers employed bovine lactoferrin as an excellent functional carrier protein for delivering doxorubicin (Dox) into DU145 cells, CD44⁺/EpCAM⁺ double positive enriched DU145 3D prostaspheres and drug resistant ADR1000-DU145 cells, thus circumventing Dox efflux, to overcome chemo-resistance. [Sci Rep] Full Article

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Role of RbBP5 and H3K4me3 in the Vicinity of Snail Transcription Start Site during Epithelial-Mesenchymal-Transition in Prostate Cancer Cells

Scientists found that in the process of TGF-Beta1 induced epithelial-mesenchymal transition in the prostate cancer cell line DU145, H3K4me3 enrichment and RbBP5 binding increased in the vicinity of Snail transcription start site. [Oncotarget] Full Article

IκB-Kinase-Epsilon (IKKε) Over-Expression Promotes the Growth of Prostate Cancer through the C/EBP-β Dependent Activation of IL-6 Gene Expression

Investigators validated the impact of IKKε depletion on the in vitro proliferation of castrate-resistant prostate cancer cells, and characterized how IKKε depletion affects tumor growth and IL-6 tumor secretion in vivo through a mouse xenograft-based approach. [Oncotarget] Full Article

Sintokamide A Is a Novel Antagonist of Androgen Receptor that Uniquely Binds Activation Function-1 in its Amino-Terminal Domain

Researchers provided evidence that sintokamide A (SINT1) binds androgen receptor (AR) AF-1 region to specifically inhibit transactivation of AR N-terminal domain. Consistent with SINT1 targeting AR AF-1, it attenuated transcriptional activities of both full-length AR as well as constitutively active AR splice variants which correlated with inhibition of growth of enzalutamide-resistant prostate cancer cells expressing AR splice variants. [J Biol Chem] Abstract | Full Article

Anti-Cancer Effect of Pristimerin by Inhibition of HIF-1α Involves the SPHK-1 Pathway in Hypoxic Prostate Cancer Cells

Scientists investigated the molecular mechanisms of pristimerin in association with sphingosine kinase 1 (SPHK-1)-1 pathways in hypoxic PC-3 cancer cells. Vascular endothelial growth factor production, cell cycles, and SPHK-1 activity were measured, and western blotting, an MTT assay, and an RNA interference assay were performed. [BMC Cancer] Full Article

miR-26a and miR-138 Block the G1/S Transition by Targeting the Cell Cycle Regulating Network in Prostate Cancer Cells

The influence of miR-26a and miR-138 on enhancer of zeste homolog 2 and cellular function including the impact on the cell cycle regulating network was evaluated in prostate cancer cells. [J Cancer Res Clin Oncol] Abstract

The Flavonoid Apigenin Reduces Prostate Cancer CD44⁺ Stem Cell Survival and Migration through PI3K/Akt/NF-κB Signaling

Prostate cancer stem cells (CSCs) (CD44⁺) were isolated from human prostate cancer PC3 cells using a magnetic-activated cell sorting system. PC3 and CSCs were treated with various concentrations of apigenin, docetaxel and their combinations for 48h. [Life Sci] Abstract

Androgens Induce a Distinct Response of Epithelial-Mesenchymal Transition Factors in Human Prostate Cancer Cells

The role of the androgen receptor (AR) and the effect of AR antagonist (antiandrogen) treatment on the RNA expression of key factors of epithelial-mesenchymal transition including the long non-coding RNAs DRAIC in prostate cancer cells remain elusive. Although the established AR target genes PSA and FKBP5 are strongly induced by androgens in both cell lines, both E-cadherin and vimentin mRNA levels are upregulated by androgens in LNCaP but not in C4-2 cells by short- and long-term treatments. [Mol Cell Biochem] Abstract

Synthesis of Novel C2-Symmetric Testosterone Dimers and Evaluation of Antiproliferative Activity on Androgen-Dependent and -Independent Prostate Cancer Cell Lines

A series of 7α-linked testosterone dimers were made and tested for biological activity on both androgen-dependent and androgen-independent prostate cancer cell lines. [Steroids] Abstract

CLINICAL RESEARCH

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The Evidence Review Group (ERG) produced a critical review of the clinical and cost effectiveness of prednisone/prednisolone (AAP) based on the company submission. An important question in this appraisal was, according to the ERG, whether AAP followed by docetaxel is more effective than best supportive care followed by docetaxel. [Pharmacoeconomics] Full Article

Targeting CDK9: A Promising Therapeutic Opportunity in Prostate Cancer

The reviewers focus on biological functions of CDK9, its involvement with androgen receptor, and the potential for therapeutic opportunities in prostate cancer treatment. [Endocr Relat Cancer] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

U.S. Preventative Services Task Force Chairperson, Dr. Kirsten Bibbins-Domingo to Present

The Prostate Health Education Network (PHEN) has announced that U.S. Preventative Task Force Chairperson (USPSTF), Kirsten Bibbins-Domingo, Ph.D, M.D., M.A.S. will address its Summit. Dr. Bibbins-Domingo will provide some insight into the USPSTF’s current process of updating its 2012 recommendation against PSA testing during the Summit session: “Prostate Cancer Early Detection PSA Testing – The Next Chapter. [Press release from the Prostate Health Education Network (PHEN) [PR Newswire Association LLC] discussing research presented at PHEN’s 12^th Annual African American Prostate Cancer Disparity Summit, Washington D.C.] Press Release

SRS Medical Receives CE Mark Approval for Spanner Prostate Stent

SRS Medical Systems, Inc., announced that it has received CE mark approval for use of its Spanner^® Temporary Prostatic Stent across the European Economic Area. The Spanner is an alternative to both indwelling and intermittent urinary catheters for male patients with bladder outlet obstruction. [SRS Medical Systems, Inc.] Press Release

GTx Appoints Dr. Garry Neil to Board of Directors

GTx, Inc. announced that Garry A. Neil, M.D., Chief Scientific Officer, Medgenics, Inc., has been appointed to the GTx, Inc. Board of Directors. Dr. Neil brings significant medical and drug development leadership to the GTx Board of Directors and a proven track record of turning new science into breakthrough commercial products. [GTx, Inc.] Press Release

Whistleblower Sues Duke, Claims Doctored Data Helped Win $200 Million in Grants

On a Friday in March 2013, a researcher working in the lab of a prominent pulmonary scientist at Duke University in Durham, North Carolina, was arrested on charges of embezzlement. The researcher, biologist Erin Potts-Kant, later pled guilty to siphoning more than $25,000 from the Duke University Health System, buying merchandise from Amazon, Walmart, and Target—even faking receipts to legitimize her purchases. A state judge ultimately levied a fine, and sentenced her to probation and community service. [ScienceInsider] Editorial

Culture of Silence Protected Disgraced Trachea Surgeon

A “star surgeon” who implanted the world’s first artificial trachea — but has since been dismissed following allegations of scientific and clinical misconduct — worked in an environment that provided a “culture of silence”, a lack of respect for rules and “group thinking”. [Nature News] Editorial

FDA Reaches Agreement with Generics Industry on New GDUFA Commitments

The Food and Drug Administration and the generic drug manufacturing industry — including representatives of generic pharmaceutical manufacturers, active pharmaceutical ingredient manufacturers and contract manufacturing organizations — have reached agreement on a package of program enhancements and resource commitments to reauthorize the Generic Drug User Fee Amendments of 2012 (GDUFA), which are set to expire next year. [Drug Store News] Editorial

NSF Proposes Changes in Use of Costly Rotators for Senior Positions

The National Science Foundation (NSF) believes that having academics spend anywhere from two to four years at the agency before returning to campus helps it identify and fund cutting-edge research. Last year 176 scientists, about 28% of NSF’s scientific workforce, were on such temporary assignments. But NSF’s heavy use of these so-called rotators is unique among government research agencies. And some members of Congress are worried that the government is paying too steep a price for that management strategy. [ScienceInsider] Editorial

NEW Advanced Prostate Cancer Consensus Conference (APCCC) 2017
March 9, 2016
St. Gallen, Switzerland

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow(s) – Uterine Fibroids and Prostate Cancer (University of Texas Health Science Center at San Antonio)

Research Intern – Prostate Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Prostate Cancer (Oregon Health & Science University)

Professor – Prostate Cancer Research (Boston University School of Medicine)

Postdoctoral Researcher – Tumor Biology (LSU Health Sciences Center)

Research Scientist – Functional Cancer Genomics (Institute of Oncology Research – Bellinzona)

Senior VP and Director Clinical Research – Oncology (Fred Hutchinson Cancer Research Center)

Assistant/Associate Professor – Genitourinary Cancers (The University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Breast, Prostate and Pancreatic Cancer (MD Anderson Cancer Center)

Associate Editor (PLOS ONE)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.